Skip to main content

DS8201-A-U206 DS8201-A-U206: A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

NCT04644237

DS8201-A-U206: A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Daiichi Sankyo Inc. - DS8201-A-U206

This study is considering willing participants who have human epidermal growth factor receptor 2 (HER2)-mutant metastatic non-small cell lung cancer (NSCLC) that has reoccurred or progressed after platinum treatment. The main purpose of this study is to gather information about an investigational drug called Trastuzumab Deruxtecan and to see if Trastuzumab Deruxtecan is effective and safe in treating your type of NSCLC.